Display options
Cite
Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol. 2013;4:21doi: 10.3389/fphar.2013.00021.
Rak, J. (2013). Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Frontiers in pharmacology, 421. https://doi.org/10.3389/fphar.2013.00021
Rak, Janusz. "Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer." Frontiers in pharmacology vol. 4 (2013): 21. doi: https://doi.org/10.3389/fphar.2013.00021
Rak J. Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer. Front Pharmacol. 2013 Mar 06;4:21. doi: 10.3389/fphar.2013.00021. eCollection 2013. PMID: 23508692; PMCID: PMC3589665.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2013 Mar 06;4:21. doi: 10.3389/fphar.2013.00021. eCollection 2013.

Extracellular vesicles - biomarkers and effectors of the cellular interactome in cancer.

Frontiers in pharmacology

Janusz Rak

Affiliations

  1. The Research Institute of the McGill University Health Centre, Montreal Children's Hospital, McGill University Montreal, QC, Canada.

PMID: 23508692 PMCID: PMC3589665 DOI: 10.3389/fphar.2013.00021

Abstract

In multicellular organisms both health and disease are defined by patterns of communication between the constituent cells. In addition to networks of soluble mediators, cells are also programed to exchange complex messages pre-assembled as multimolecular cargo of membraneous structures known extracellular vesicles (EV). Several biogenetic pathways produce EVs with different properties, and known as exosomes, ectosomes, and apoptotic bodies. In cancer, EVs carry molecular signatures and effectors of the disease, such as mutant oncoproteins, oncogenic transcripts, microRNA, and DNA sequences. Intercellular trafficking of such EVs (oncosomes) may contribute to horizontal cellular transformation, phenotypic reprograming, and functional re-education of recipient cells, both locally and systemically. The EV-mediated, reciprocal molecular exchange also includes tumor suppressors, phosphoproteins, proteases, growth factors, and bioactive lipids, all of which participate in the functional integration of multiple cells and their collective involvement in tumor angiogenesis, inflammation, immunity, coagulopathy, mobilization of bone marrow-derived effectors, metastasis, drug resistance, or cellular stemness. In cases where the EV role is rate limiting their production and uptake may represent and unexplored anticancer therapy target. Moreover, oncosomes circulating in biofluids of cancer patients offer an unprecedented, remote, and non-invasive access to crucial molecular information about cancer cells, including their driver mutations, classifiers, molecular subtypes, therapeutic targets, and biomarkers of drug resistance. New nanotechnologies are being developed to exploit this unique biomarker platform. Indeed, embracing the notion that human cancers are defined not only by processes occurring within cancer cells, but also between them, and amidst the altered tumor and systemic microenvironment may open new diagnostic and therapeutic opportunities.

Keywords: cancer; cellular interactions; exosomes; extracellular vesicles; oncogenes

References

  1. Thromb Haemost. 2012 Jul;108(1):160-5 - PubMed
  2. Ann Neurol. 2012 Oct;72(4):610-24 - PubMed
  3. J Thromb Haemost. 2012 Jul;10(7):1363-70 - PubMed
  4. J Neurooncol. 2011 Aug;104(1):225-31 - PubMed
  5. Anticancer Res. 2005 Nov-Dec;25(6A):3703-7 - PubMed
  6. Nat Cell Biol. 2008 Dec;10(12):1470-6 - PubMed
  7. Cell. 2012 Dec 21;151(7):1542-56 - PubMed
  8. Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2383-90 - PubMed
  9. Cell. 2005 Dec 16;123(6):1001-11 - PubMed
  10. Cancer Sci. 2010 Oct;101(10):2087-92 - PubMed
  11. Cancer Cell. 2011 Dec 13;20(6):810-7 - PubMed
  12. Commun Integr Biol. 2012 Jan 1;5(1):88-93 - PubMed
  13. Cancer Res. 2012 Oct 1;72(19):4920-30 - PubMed
  14. Nucleic Acids Res. 2012 Oct;40(18):9125-38 - PubMed
  15. N Engl J Med. 2008 Dec 25;359(26):2814-23 - PubMed
  16. BMC Cancer. 2012 Jan 17;12:22 - PubMed
  17. Nat Cell Biol. 2010 Jan;12(1):19-30; sup pp 1-13 - PubMed
  18. Cell. 2008 Jun 13;133(6):994-1005 - PubMed
  19. J Transl Med. 2012 Jun 27;10:134 - PubMed
  20. Nature. 2012 Feb 15;482(7386):529-33 - PubMed
  21. Cell. 2010 Apr 2;141(1):39-51 - PubMed
  22. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  23. Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3794-9 - PubMed
  24. Genes Dev. 2010 Aug 15;24(16):1731-45 - PubMed
  25. Cancer Res. 2004 Nov 15;64(22):8249-55 - PubMed
  26. Science. 2003 May 16;300(5622):1155-9 - PubMed
  27. Nat Rev Cancer. 2011 Jun;11(6):426-37 - PubMed
  28. Neoplasia. 2009 Oct;11(10):1093-105 - PubMed
  29. J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24 - PubMed
  30. Curr Opin Oncol. 2008 Jan;20(1):104-11 - PubMed
  31. Cancer Res. 2006 May 1;66(9):4795-801 - PubMed
  32. Nature. 1956 Dec 22;178(4547):1391-2 - PubMed
  33. Sci Signal. 2012 Sep 25;5(243):ra70 - PubMed
  34. Curr Biol. 2009 Dec 1;19(22):1875-85 - PubMed
  35. Science. 2008 Feb 29;319(5867):1244-7 - PubMed
  36. Nat Med. 2012 Dec;18(12):1835-40 - PubMed
  37. Blood Cells Mol Dis. 2006 Mar-Apr;36(2):315-21 - PubMed
  38. Blood Rev. 2007 May;21(3):157-71 - PubMed
  39. N Engl J Med. 2012 Mar 8;366(10):883-892 - PubMed
  40. Nat Rev Cancer. 2003 Jun;3(6):453-8 - PubMed
  41. Science. 2011 Apr 15;332(6027):354-8 - PubMed
  42. J Cell Biol. 2010 Sep 20;190(6):1079-91 - PubMed
  43. Drug Resist Updat. 2003 Jun;6(3):111-27 - PubMed
  44. Brain Pathol. 2004 Apr;14(2):131-6 - PubMed
  45. Nat Biotechnol. 2011 Apr;29(4):341-5 - PubMed
  46. Nat Med. 2008 May;14(5):518-27 - PubMed
  47. Nat Med. 2004 Aug;10(8):789-99 - PubMed
  48. Clin Cancer Res. 2007 Aug 15;13(16):4909-19 - PubMed
  49. Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):728-33 - PubMed
  50. Cancer Res. 2006 Jul 15;66(14):7083-94 - PubMed
  51. J Natl Cancer Inst. 1989 May 3;81(9):648-9 - PubMed
  52. Proc Natl Acad Sci U S A. 1980 Jan;77(1):399-403 - PubMed
  53. Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4852-7 - PubMed
  54. Kidney Int. 2010 Nov;78(9):838-48 - PubMed
  55. Int J Cancer. 2005 Feb 20;113(5):752-60 - PubMed
  56. PLoS Biol. 2012;10(12):e1001450 - PubMed
  57. Nature. 1984 Jun 7-13;309(5968):552-6 - PubMed
  58. Nat Rev Cancer. 2008 Aug;8(8):592-603 - PubMed
  59. Proc Natl Acad Sci U S A. 2001 May 22;98(11):6407-11 - PubMed
  60. Cancer Metastasis Rev. 1989 Aug;8(2):98-101 - PubMed
  61. Biochem Pharmacol. 2011 May 15;81(10):1171-82 - PubMed
  62. Blood. 2008 Dec 15;112(13):4793-807 - PubMed
  63. FASEB J. 2012 Jan;26(1):420-9 - PubMed
  64. Nat Rev Mol Cell Biol. 2011 Feb;12(2):104-17 - PubMed
  65. J Cell Sci. 2005 Jul 1;118(Pt 13):2849-58 - PubMed
  66. FASEB J. 2009 May;23(5):1541-57 - PubMed
  67. Nature. 2005 Dec 8;438(7069):820-7 - PubMed
  68. Nat Rev Cancer. 2006 Feb;6(2):141-6 - PubMed
  69. Diabetes Metab Syndr Obes. 2012;5:247-82 - PubMed
  70. Oncogene. 2012 Aug 23;31(34):3889-900 - PubMed
  71. Blood. 2012 Aug 23;120(8):1678-86 - PubMed
  72. Mol Cell Proteomics. 2013 Feb;12(2):343-55 - PubMed
  73. Med Hypotheses. 2006;66(3):601-4 - PubMed
  74. Cancer Res. 2006 Jan 15;66(2):867-74 - PubMed
  75. Ann Oncol. 2004;15 Suppl 4:iv141-4 - PubMed
  76. Blood. 2005 Feb 15;105(4):1734-41 - PubMed
  77. Cancer Res. 1990 Dec 15;50(24):8017-22 - PubMed
  78. Br J Cancer. 2005 Jan 31;92(2):305-11 - PubMed
  79. Exp Oncol. 2006 Jun;28(2):126-31 - PubMed
  80. Gynecol Oncol. 2008 Jul;110(1):13-21 - PubMed
  81. Nat Cell Biol. 2007 Jun;9(6):654-9 - PubMed
  82. Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6328-33 - PubMed
  83. Bioessays. 2012 Jun;34(6):489-97 - PubMed
  84. Cancer Res. 2009 Jul 1;69(13):5601-9 - PubMed
  85. Lancet Oncol. 2012 Apr;13(4):e178-85 - PubMed
  86. Mol Ther. 2011 Oct;19(10):1769-79 - PubMed
  87. Trends Mol Med. 2004 Apr;10(4):171-8 - PubMed
  88. Blood. 2010 Sep 30;116(13):2385-94 - PubMed
  89. Science. 1976 Oct 1;194(4260):23-8 - PubMed
  90. Ital J Anat Embryol. 2005;110(2 Suppl 1):127-33 - PubMed
  91. Nat Protoc. 2012 Dec;7(12):2112-26 - PubMed
  92. Eur J Clin Invest. 2004 Jun;34(6):392-401 - PubMed
  93. EMBO J. 2009 Apr 22;28(8):1043-54 - PubMed
  94. N Engl J Med. 2008 Jul 31;359(5):492-507 - PubMed
  95. Blood. 2012 Jun 7;119(23):5543-52 - PubMed
  96. Nat Commun. 2011 Feb 01;2:180 - PubMed
  97. J Natl Cancer Inst. 2010 Jun 16;102(12):866-80 - PubMed
  98. J Am Soc Nephrol. 2009 Feb;20(2):363-79 - PubMed
  99. Nat Rev Immunol. 2009 Aug;9(8):581-93 - PubMed
  100. Oncogene. 2012 Nov 8;31(45):4740-9 - PubMed
  101. J Cell Physiol. 2012 Feb;227(2):658-67 - PubMed
  102. Nat Cell Biol. 2008 May;10(5):619-24 - PubMed
  103. Nat Rev Cancer. 2012 Apr 05;12(5):349-61 - PubMed
  104. Biochim Biophys Acta. 2006 Mar;1763(3):330-5 - PubMed
  105. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3585-9 - PubMed
  106. Clin Cancer Res. 2012 Apr 1;18(7):1901-13 - PubMed
  107. Thromb Haemost. 2007 Nov;98(5):1096-107 - PubMed
  108. Clin Dev Immunol. 2011;2011:842849 - PubMed
  109. Nat Med. 2012 Jun;18(6):883-91 - PubMed
  110. Adv Cancer Res. 2004;91:1-30 - PubMed
  111. Brain Pathol. 2009 Jan;19(1):132-43 - PubMed
  112. Cancer Metastasis Rev. 1990 Jul;9(1):21-34 - PubMed
  113. Cancer Cell. 2006 Mar;9(3):157-73 - PubMed
  114. EMBO J. 2011 Jun 1;30(11):2115-29 - PubMed
  115. Cancer Res. 2011 Jun 1;71(11):3792-801 - PubMed
  116. Dev Cell. 2007 Dec;13(6):759-60 - PubMed
  117. Nat Med. 2012 Aug;18(8):1232-8 - PubMed
  118. Nature. 2010 Jan 28;463(7280):545-8 - PubMed
  119. Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20370-5 - PubMed
  120. Biochem Biophys Res Commun. 2010 May 21;396(1):147-51 - PubMed
  121. Nat Rev Clin Oncol. 2009 Jun;6(6):352-66 - PubMed
  122. Leukemia. 2009 Sep;23(9):1643-9 - PubMed
  123. N Engl J Med. 2005 Nov 10;353(19):2012-24 - PubMed
  124. Blood. 2007 Oct 1;110(7):2440-8 - PubMed
  125. Methods Mol Biol. 2011;728:235-46 - PubMed
  126. Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5872-7 - PubMed
  127. Nat Cell Biol. 2012 Oct;14(10):1036-45 - PubMed
  128. J Biol Chem. 2012 Dec 21;287(52):43565-72 - PubMed
  129. Blood. 2010 Mar 4;115(9):1755-64 - PubMed
  130. Science. 2007 Nov 16;318(5853):1108-13 - PubMed
  131. Leukemia. 2006 Sep;20(9):1487-95 - PubMed
  132. Mol Ther. 2013 Jan;21(1):185-91 - PubMed
  133. Nature. 2012 Apr 18;486(7403):346-52 - PubMed
  134. Nature. 2012 Jan 18;481(7381):306-13 - PubMed
  135. Cell Death Differ. 2008 Nov;15(11):1723-33 - PubMed

Publication Types